SG11201609739UA - Derivatives of dolaproine-dolaisoleuine peptides - Google Patents

Derivatives of dolaproine-dolaisoleuine peptides

Info

Publication number
SG11201609739UA
SG11201609739UA SG11201609739UA SG11201609739UA SG11201609739UA SG 11201609739U A SG11201609739U A SG 11201609739UA SG 11201609739U A SG11201609739U A SG 11201609739UA SG 11201609739U A SG11201609739U A SG 11201609739UA SG 11201609739U A SG11201609739U A SG 11201609739UA
Authority
SG
Singapore
Prior art keywords
dolaisoleuine
dolaproine
peptides
derivatives
dolaisoleuine peptides
Prior art date
Application number
SG11201609739UA
Other languages
English (en)
Inventor
Brian Alan Mendelsohn
Julien Dugal-Terrier
Stuart Daniel Barnscher
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of SG11201609739UA publication Critical patent/SG11201609739UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201609739UA 2014-05-28 2015-05-27 Derivatives of dolaproine-dolaisoleuine peptides SG11201609739UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004084P 2014-05-28 2014-05-28
PCT/US2015/032704 WO2015183978A1 (en) 2014-05-28 2015-05-27 Derivatives of dolaproine-dolaisoleuine peptides

Publications (1)

Publication Number Publication Date
SG11201609739UA true SG11201609739UA (en) 2016-12-29

Family

ID=54699722

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609739UA SG11201609739UA (en) 2014-05-28 2015-05-27 Derivatives of dolaproine-dolaisoleuine peptides

Country Status (9)

Country Link
US (2) US20170190735A1 (https=)
EP (1) EP3149024B9 (https=)
JP (3) JP2017519740A (https=)
KR (1) KR102413079B1 (https=)
CN (1) CN107041139A (https=)
ES (1) ES2883023T3 (https=)
RU (1) RU2747989C2 (https=)
SG (1) SG11201609739UA (https=)
WO (1) WO2015183978A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3149024B9 (en) * 2014-05-28 2021-10-27 Agensys, Inc. Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
EP4321522A1 (en) * 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
AU2024267769A1 (en) * 2023-05-06 2025-10-16 Remegen Co., Ltd. Preparation method for intermediate of auristatin derivative

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232552T2 (de) * 1991-08-09 2002-10-31 Teikoku Hormone Mfg. Co., Ltd. Tetrapeptide Derivat
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH06234790A (ja) * 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd 新規テトラペプチドアミド誘導体
KR100332254B1 (ko) * 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5521284A (en) * 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6323315B1 (en) * 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ATE459364T1 (de) 2003-10-22 2010-03-15 Univ Johns Hopkins Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
KR20070050918A (ko) * 2004-07-02 2007-05-16 뉴텍 파마 피엘씨 암의 치료
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
CN101242816B (zh) * 2005-06-30 2012-10-31 维罗贝股份有限公司 Hcv抑制剂
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
JP5171621B2 (ja) * 2005-07-07 2013-03-27 シアトル ジェネティックス, インコーポレイテッド フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物
CN106986926A (zh) 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
EP2265283B1 (en) * 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP2276509B1 (en) 2008-04-11 2016-06-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
RU2566693C2 (ru) * 2011-07-08 2015-10-27 Сименс Акциенгезелльшафт Система слоев с двухслойным металлическим слоем
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
US9981046B2 (en) * 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
HK1214282A1 (zh) * 2012-11-07 2016-07-22 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
CN104936621A (zh) 2012-11-07 2015-09-23 辉瑞公司 抗IL-13受体α2抗体和抗体-药物缀合物
EP3149024B9 (en) * 2014-05-28 2021-10-27 Agensys, Inc. Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer

Also Published As

Publication number Publication date
JP2017519740A (ja) 2017-07-20
KR102413079B1 (ko) 2022-06-24
RU2747989C2 (ru) 2021-05-18
WO2015183978A1 (en) 2015-12-03
EP3149024A1 (en) 2017-04-05
JP7292366B2 (ja) 2023-06-16
JP2022027896A (ja) 2022-02-14
US20220204557A1 (en) 2022-06-30
EP3149024B9 (en) 2021-10-27
US20200325170A1 (en) 2020-10-15
CN107041139A (zh) 2017-08-11
JP2020128405A (ja) 2020-08-27
RU2016150426A3 (https=) 2018-12-20
JP6995160B2 (ja) 2022-01-14
US20170190735A1 (en) 2017-07-06
US11312748B2 (en) 2022-04-26
KR20170005495A (ko) 2017-01-13
ES2883023T3 (es) 2021-12-03
RU2016150426A (ru) 2018-07-03
EP3149024A4 (en) 2018-06-06
EP3149024B1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
SG11201706729SA (en) Derivatives of sobetirome
SI3845221T1 (sl) Trdne oblike sofosbuvirja
GB201418562D0 (en) Peptides
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3418273T3 (pl) Pochodne flawaglin
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL246979A0 (en) Crystalline forms of sofosbuvir
GB201401877D0 (en) Peptides
SG11201608634RA (en) Cycloalkyl-linked diheterocycle derivatives
SMT201900438T1 (it) Nuovi derivati di cyp-eicosanoide
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
GB201503483D0 (en) Novel Antimmicrobial Peptides
IL249130A0 (en) Preparation of piperidine-4-carbthioamide
GB201410686D0 (en) Peptides
IL249332A0 (en) Crystalline forms of sofosbuvir
GB201504211D0 (en) Use of peptides
GB201420645D0 (en) Peptides
GB201412731D0 (en) Peptides
GB201409010D0 (en) Peptides
GB201405078D0 (en) Peptides
GB201415235D0 (en) Trans-locating peptide
GB201404910D0 (en) Trans-locating peptide
GB201412797D0 (en) Proteins